On April 27, 2022 Alligator Bioscience AB reported that Interim report January–March 2022 (Press release, Alligator Bioscience, APR 27, 2022, View Source [SID1234613014])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SIGNIFICANT EVENTS JANUARY-MARCH

Pipeline:

In March, the Company successfully completed the Phase Ib part of the clinical study OPTIMIZE-1, and Phase II is now enrolling patients at the recommended dose of 900 µg/kg.
In January, Alligator initiated a sponsored research collaboration with Dr. Beatty of University of Pennsylvania to support OPTIMIZE-1, and at the same time we welcomed Dr. Beatty as advisor to Alligator.
Company:

Sumeet Ambarkhane was appointed as new Chief Medical Officer to strengthen Alligator’s efforts to further advance the development of our novel immuno-oncology pipeline in the coming year.
The Nomination Committee proposed that the Annual General Meeting 2022 re-elects the current board members, and that Staffan Encrantz and Denise Goode are elected as new board members.
SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

On April 1, Alligator announced the completion of the 600 mg dose cohort for ATOR-1017, where data indicates no significant safety concerns, with stable disease as the best tumor response. Patient enrollment and treatment for the highest planned dose cohort, 900 mg, has commenced.
FINANCIAL SUMMARY

January–March 2022

Net sales, SEK 5.4 million (0.6)
Operating profit/loss, SEK -43.0 million (-32.5)
Profit/loss for the period, SEK -43.1 million (-32.7)
Earnings per share before and after dilution, SEK -0.20 (-0.42)*
Cash flow for the period, SEK -43.8 million (40.4)
Cash and cash equivalents, SEK 234.4 million (278.1)
*) Previous periods have been adjusted, see Note 8, page 20 in the attached report.

The full report is attached as PDF available on the company’s website: View Source

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CET on April 27, 2022.

On April 27, 2022 United Therapeutics Corporation (Nasdaq: UTHR) reported that it will report its first quarter 2022 financial results before the market opens on Wednesday, May 4, 2022 (Press release, United Therapeutics, APR 27, 2022, View Source [SID1234613012]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

United Therapeutics will host a public webcast Wednesday, May 4, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics’ website at View Source A rebroadcast of the webcast will be available for one week and can be accessed at the same location.

On April 27, 2022 ISA reported that its representatives will be participating and presenting at the following business conferences in May 2022 (Press release, ISA Pharmaceuticals, APR 27, 2022, View Source [SID1234613011]). If you would like to meet with our team at any of these events, please contact us through the conference partnering systems or via [email protected].

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LSX World Leaders Congress

Date: 10-11 May 2022, London, UK

Panel Presentation by: Anton Mat, Director Business Development, ISA Pharmaceuticals

Title: Key Multi-Stakeholder Considerations In Early-Stage Commercial Deal-Making

Date & Time: Tuesday, 10 May 2022, 14.30pm BST

Bio€quity Europe

Date: 16-18 May 2022, Milan, Italy

Presentation by: Gerben Moolhuizen, Chief Executive Officer, ISA Pharmaceuticals

Date & Time: Virtual, pre-recorded presentation available any time via the partnering system

UBS Global Healthcare Conference

Date: 23-25 May 2022, New York, US

Presentation by: Gerben Moolhuizen, Chief Executive Officer, ISA Pharmaceuticals

Title: ISA Pharmaceuticals Company Presentation

Date & Time: Monday, 23 May 2022, 07.45am ET

On April 27, 2022 Cellectis (the "Company") (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported that its partner Cytovia Therapeutics, LLC ("Cytovia"), a biopharmaceutical company empowering natural killer ("NK") cells to fight cancer through stem cell engineering and multispecific antibodies, entered into a definitive business combination agreement with Isleworth Healthcare Acquisition Corp. (NASDAQ: ISLE) ("Isleworth"), a Special Purpose Acquisition Company ("SPAC") (Press release, Cellectis, APR 27, 2022, View Source [SID1234613010]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Concurrent with the business combination agreement, Cellectis received a $20 million convertible note in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement entered between Cellectis and Cytovia in February 2021. The terms of the note provide for conversion into common stock of the combined company upon completion of the business combination, which is subject to the satisfaction or waiver of customary closing conditions. In connection with this convertible note, Cellectis received a warrant to purchase additional shares of the combined company representing up to 35% of the shares issued upon conversion of the note at a predetermined exercise price, with the number of shares issuable upon exercise and the exercise subject to certain adjustments.

« We are impressed by the progress Cytovia has accomplished in the past months. Cytovia shares Cellectis’ mission to provide life-saving off-the-shelf allogeneic cell therapies to patients, and we are excited to be providing them with best-in-class TALEN gene editing for cell therapy applications. Congratulations to the Cytovia team for this transaction, which is an important milestone as they continue their journey to progress gene-edited NK therapeutics towards a cure for cancer! » said André Choulika, CEO of Cellectis.

Cellectis and Cytovia’s research and development collaboration:

In February 2021, Cellectis and Cytovia entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells. In November 2021, Cellectis and Cytovia extended their collaboration to include new CAR target and development in China by Cytovia’s strategic partner, CytoLynx Therapeutics.

Financial terms of the collaboration include the $20 million convertible note as well as up to $805 million of development, regulatory, and sales milestones and single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia.

Cellectis is developing custom TALEN, which Cytovia uses to edit iPSCs. Cytovia is responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and is conducting the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis has granted Cytovia a worldwide license under the patent rights over which Cellectis has control in this field, including in China, in order for Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.

On April 27, 2022 Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), reported that the company’s annual report and corporate governance report for the financial year 2021 are now available on the company’s website, www.isofolmedical.com (View Source) (Press release, Isofol Medical, APR 27, 2022, View Source [SID1234613009]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CEST on April 27, 2022.

About arfolitixorin
Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global pivotal Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.